brostallicin (PNU-166196) / SOBI - LARVOL DELTA

First-line chemotherapy in advanced intrabdominal well-differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis. (PubMed, Cancer) - "Cytotoxic chemotherapy, in particular anthracycline alone, had marginal activity in advanced IA-LPS. Ifosfamide-containing regimens showed higher activity, although it was not statistically significant and in a small number of cases, with the combination of doxorubicin and ifosfamide appearing to be the more active regimen available in fit patients. This series provides a benchmark for future trials on new drugs in WD/DD liposarcoma."

Journal • Retrospective data • Liposarcoma • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

[VIRTUAL] First-line chemotherapy (CT) in advanced well-differentiated/dedifferentiated liposarcoma (WD/DD LPS): An EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis (ESMO 2020) - "Treatment was aggregated into 5 groups: anthracycline (A) alone (Doxorubicin (D) 75 mg/m2, Caelyx 50 mg/m2, Epirubicin 75 mg/m2, Epirubicin 150 mg/m2), Ifosfamide (IFO) alone (IFO 5 g/m2, IFO 9 g/m2, IFO 12 g/m2), D+IFO (D 50 mg/m2+IFO 5 g/m2, D 75 mg/m2+IFO 5 g/m2, DOX 75 mg/m2+IFO 10 g/m2), D+cyclophosphamide+vincristine+DTIC (CYVADIC), “other” (brostallicin, trabectedin). Legal entity responsible for the study: EORTC Soft Tissue and Bone Sarcoma Group. Funding: Has not received any funding."

Retrospective data • Liposarcoma • Oncology • Osteosarcoma • Sarcoma • Solid Tumor